Explore 3 Stock Ideas & Industry Insights Download Free Report

Disc Medicine Inc.

Company price
77.0096 USD -0.97 ( 1.24%)
Last update at 2026-11-19T15:35:00Z
VOLUME
50080
Market Cap
849.19M

Momentum Score

…

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
76.95
Low
79.02
High
52 Week Price Range
25.60
Low
77.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

I cannot find reliable public information confirming a NASDAQ-listed company named Disc Medicine Inc. under the ticker IRON, and available databases do not verify the firm's core business or filings. Because verifiable disclosures are lacking, I cannot reliably describe long-term growth drivers or explain why investors may find the company attractive.
The key investment risk is the absence of verifiable public filings or clear corporate identity, which prevents assessment of regulatory, clinical, operational, and financial exposures and increases the chance of misidentification.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
77.98
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-28.23%
Net Debt
-358.28M
ROCE
-13.72%
Diluted EPS TTM
-3.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -46.83M -35.97M -40.84M
Net income -46.09M -41.01M -47.66M
Selling general administrative 14.04M 5.76M 5.87M
Reconciled depreciation 0.09M 0.23M 0.32M
Ebit -47.56M -30.93M -34.04M
Ebitda -47.48M -25.85M -33.68M
Depreciation and amortization 0.09M 5.08M 0.36M
Operating income -47.48M -30.93M -34.04M
Other operating expenses 47.48M 30.93M 34.04M
Interest expense 0.74M 2.16M 6.83M
Interest income 0.71M 0.01M 0.04M
Net interest income 0.71M -2.14M -6.79M
Income tax expense -0.74M 5.04M 6.83M
Total revenue 0.00M 0.00M 0.00M
Total operating expenses 47.48M 30.93M 34.04M
Total other income expense net 0.65M -5.04M -6.80M
Net income from continuing ops -46.83M -71.87M -40.84M
Net income applicable to common shares - -35.97M -20.94M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 368.00M 200.21M 92.41M 122.09M
Other current assets 5.28M 198.49M 3.47M 0.13M
Total liab 22.88M 23.61M 156.61M 4.82M
Total stockholder equity 345.12M 176.60M -64.20M 117.27M
Other current liab 21.44M 6.11M 6.45M 0.59M
Common stock 0.00M - 0.00M 112.27M
Capital stock 0.00M 0.00M 0.00M 112.27M
Retained earnings -188.65M -112.22M -65.39M -0.81M
Other assets - - 0.18M 0.06M
Cash 360.38M 194.61M 88.04M 1.21M
Total current liabilities 21.44M 22.58M 13.42M 0.60M
Current deferred revenue -13.29M - 4.10M -
Net debt -358.28M -193.28M -86.38M -1.21M
Short term debt 0.67M 0.31M 0.32M -
Short long term debt - - 5.00M -
Short long term debt total 2.10M 1.33M 1.65M -
Other stockholder equity 533.76M 288.81M 1.19M 5.81M
Property plant equipment - - 1.75M 1.13M
Total current assets 365.66M 198.49M 90.48M 1.34M
Net tangible assets - - -64.20M -28.81M
Long term debt - - 0.40M -
Accounts payable 12.63M 16.16M 2.56M 0.00M
Accumulated other comprehensive income 0.00M - - -
Non currrent assets other 0.23M 0.12M 0.18M 120.75M
Non current assets total 2.33M 1.71M 1.93M 120.75M
Capital lease obligations 2.10M 1.33M 1.65M -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -0.15M 0.34M -0.02M
Change to liabilities - 1.31M -0.51M
Total cashflows from investing activities - -0.07M -0.08M
Total cash from financing activities 148.98M 89.93M 34.25M
Change to operating activities - -0.03M 1.01M
Net income -46.83M -35.97M -40.84M
Change in cash 106.58M 62.33M 1.52M
Begin period cash flow 88.21M 25.89M 3.31M
End period cash flow 194.79M 88.21M 4.83M
Total cash from operating activities -42.25M -27.53M -32.71M
Issuance of capital stock 53.50M 89.86M 20.08M
Depreciation 0.09M 0.03M 0.32M
Other cashflows from financing activities 95.48M 94.51M -0.02M
Change to netincome - 7.12M 0.45M
Capital expenditures 0.15M 0.07M 0.02M
Change in working capital 2.12M 1.29M 0.34M
Stock based compensation 2.09M 0.51M 0.98M
Other non cash items 0.27M 1.56M 6.48M
Free cash flow -42.40M -27.60M -32.73M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
IRON
Disc Medicine Inc.
-0.97
1.24%
77.01 - - - 2.28 -4.71
NVO
Novo Nordisk A/S
-0.34
0.86%
39.09 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.95
1.30%
529.50 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-18.50
1.96%
927.03 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Disc Medicine Inc.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

321 Arsenal Street, Watertown, MA, United States, 02472

617 674 9274

78

Name Title Year Born
Dr. Donald William Nicholson Ph.D. Executive Chairman 1959
Dr. William Jacob Savage M.D., Ph.D. Chief Medical Officer 1975
Dr. John D. Quisel Esq., J.D., Ph.D. CEO, President & Director 1971
Dr. Brian MacDonald ChB, MB, Ph.D. Founder & Chair of Scientific Advisory Board 1960
Ms. Jean M. Franchi Chief Financial Officer 1966
Mr. Jonathan Yu M.B.A. Chief Opearating Officer 1981
Dr. Rahul Khara J.D., Pharm.D. General Counsel, Compliance Officer & Secretary 1982
Mr. Srikanth Venkatraman Ph.D. Senior VP & Head of Chemistry NA
Ms. Hua Yang Ph.D. Senior Vice President of Nonclinical Development NA
Ms. Pamela Stephenson M.P.H. Chief Commercial Officer 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…